Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[11C]MPC6827 PET Imaging in Neurodegenerative Diseases
NCT04575727Phase 1Completed
- Sponsor
- Columbia University
- Start
- Jan 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [11C]MPC6827 in Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Columbia University. Primary endpoints: Biodistribution of [11C]MPC6827 up to 48 hours and Estimation of clearance of [11C]MPC6827 up to 48 hours. Started Jan 2021; status: completed.
02
Drugs
[11C]MPC6827
03
Conditions
Alzheimer's disease (AD)amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04575727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04575727.